Overview


According to FutureWise analysis, the market for Acute Renal Failure is expected to grow at a CAGR of 5.32% over the forecast period of 2023-2031.

Acute kidney failure (AKF), also known as acute renal failure (ARF) or acute kidney injury (AKI), is a disorder where there is a sudden and severe decline in kidney function. During this, the kidneys cannot effectively remove waste products from the blood, which ends up in the building of toxins in the blood, which can be life-threatening. This can lead to dangerous accumulations of waste substances and an imbalance in the chemical composition of the blood. Symptoms that are executed during acute kidney failure include reduced urine output, though occasionally urine output may remain normal, fluid retention leading to swelling in the extremities, shortness of breath, fatigue, confusion, nausea, weakness, irregular heartbeat, chest pain or pressure, and in severe cases, seizures or even coma. In some instances, acute kidney failure may be asymptomatic and only detected through lab tests for other reasons.

In terms of treatment, hospitalization is typically required for acute kidney failure. The duration of the hospital stay depends on the underlying cause and how quickly the kidneys recover. Treatment involves addressing the root cause of kidney injury and managing complications while allowing time for kidney healing. This may include therapies to regulate fluid levels, medications to control blood potassium and calcium levels, and, in some cases, temporary haemodialysis to remove toxins from the blood until kidney function is restored.

FutureWise Market Research has published a report that provides an insightful analysis of Acute Renal Failure Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Acute Renal Failure Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Abbott
  • Amgen Inc.
  • AM Pharma
  • Quark Pharma
  • Exponential Biotherapeutics
  • Baxter
  • Teva Pharmaceutical Limited Inc.
  • Pfizer
  • Novartis AG
  • LG Life Sciences

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Acute Renal Failure Market:

  • In March of 2021, C-Path revealed the initiation of a project focused on acute kidney injury, organized in collaboration with the U.S. Food and Drug Administration (FDA) divisions, including Drug Evaluation and Research, the Office of Translational Science, and the Division of Cardiology and Nephrology. This venture aims to create a set of predictive tools to enhance the identification of drug-induced kidney damage.
  • Then, in June 2021, Acinonyx reported the enrollment of the inaugural participant in its Phase-2a clinical trial featuring CER-001. This trial targets to assess the efficacy of CER-001 in treating septic patients with a heightened risk of developing acute kidney injury.

The growing incidence of acute renal failure diseases and the prevalence of conditions such as sepsis, heart failure, and kidney infections exaggerating renal failure drive the demand of this market. Technological advancements such as medical devices, improvised dialysis machines, and renal replacement therapies are propelling the market growth. Geriatric populations are more prone to these renal diseases and other conditions that lead to renal failure, and the rise in their population globally is positively affecting the market. Increases in healthcare expenditure and more significant investments in critical care and nephrology services benefit the renal failure market. Government initiatives and campaigns organized by them not only help create awareness but also aid in early diagnosis of the disease and risk factors associated with them, helping the individual and the healthcare professional better, thus bolstering the market.

However, factors such as high treatment costs associated with renal failure treatment, including hospitalizations, dialysis, and potential transplantations, can deter the patient and constrain the market growth. Limiting accessibility in low-income regions due to inadequate healthcare infrastructure and expenditure lack of skilled and trained professionals hinders market growth.

By Treatment Type

  • Dialysis
  • Medication
  • Kidney Transplantation

By End User

  • Dialysis Centres
  • Hospitals
  • Clinics
  • Research and Academic Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America holds the largest market share due to the surging incidence of diseases such as acute kidney injury in this region. The rise in the geriatric patient population also affects the growth in this region as they are more prone to renal diseases; expanded healthcare infrastructure, the surge in healthcare expenditure, and increased research and development are occurring, which is enhancing the treatment modalities and interventions with more innovations in this region which is driving the market. In addition, government initiatives and approval for the new products and a surge in the adoption of these products are propelling the market growth in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Acute Renal Failure Market By Treatment Type, By End User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Acute Renal Failure Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Renal Failure Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.  Acute Renal Failure Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Acute Renal Failure Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Dialysis
        2. Medication
        3. Kidney Transplantation

  • 8.  Acute Renal Failure Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Dialysis Centres
        2. Hospitals
        3. Clinics
        4. Research and Academic Institutes

  • 9.   North America Acute Renal Failure Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Acute Renal Failure Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Acute Renal Failure Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Acute Renal Failure Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Acute Renal Failure Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AM Pharma
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Quark Pharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Exponential Biotherapeutics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Baxter
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Teva Pharmaceutical Limited Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. LG Life Sciences
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients